Comparative Pharmacology
Head-to-head clinical analysis: PYOCIDIN versus TRIMPEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PYOCIDIN versus TRIMPEX.
PYOCIDIN vs TRIMPEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pyocidin is a bactericidal antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
Inhibits dihydrofolate reductase, blocking the conversion of dihydrofolic acid to tetrahydrofolic acid, thereby inhibiting bacterial thymidine synthesis and DNA replication.
5 mg/kg intramuscular or subcutaneous every 24 hours. Max dose 300 mg per injection.
5 mg/kg orally every 6 hours for acute infections; 5 mg/kg orally every 12 hours for chronic urinary tract infections.
None Documented
None Documented
Terminal elimination half-life is 2-3 hours in patients with normal renal function; extends to 12-18 hours in severe renal impairment (CrCl <30 mL/min).
8-11 hours; prolonged in renal impairment (creatinine clearance <10 mL/min: 20-40 hours)
Primarily renal excretion of unchanged drug (60-70%), with 20-30% biliary excretion and minor fecal elimination (<10%).
Renal: 40-70% as unchanged drug; biliary/fecal: minimal (10-15% as metabolites)
Category C
Category C
Antibiotic
Antibiotic